Company Overview of OrthoCyte Corporation
OrthoCyte Corporation develops novel therapeutics based on stem cell technology for the treatment of injuries and disorders affecting the musculoskeletal system, including therapeutics that would regenerate bone, cartilage, tendons and ligaments. The company was founded in 2010 and is based in Alameda, California. OrthoCyte Corporation operates as a subsidiary of BioTime, Inc.
1301 Harbor Bay Parkway
Alameda, CA 94502
Founded in 2010
Key Executives for OrthoCyte Corporation
Chief Executive Officer of Biotime
Vice President of Research and Business Development
Compensation as of Fiscal Year 2015.
OrthoCyte Corporation Key Developments
Heraeus Medical GmbH and OrthoCyte Corporation Enter into Exclusive Worldwide Development and Licensing Agreements
Sep 30 15
Heraeus Medical GmbH and BioTime Inc. announced that BioTime’s subsidiary OrthoCyte Corporation and Heraeus Medical have entered into exclusive development and worldwide licensing agreements for the development of innovative bone grafting therapies based on the use of BioTime’s proprietary PureStem human embryonic progenitor cell technology. Under the terms of the development agreement, Heraeus Medical would make an initial $1 million upfront payment to OrthoCyte, and additional payments upon OrthoCyte’s attainment of certain product development milestones, and Heraeus will fund all ongoing product development activities through IND submission. Heraeus Medical, with its global marketing capability, will be responsible for worldwide sales if a product is successfully developed, can be demonstrated through clinical trials to be safe and effective, and receives regulatory approval for marketing. OrthoCyte will be responsible for product development and initially for manufacturing. Pursuant to the terms of the license agreement, OrthoCyte has licensed certain technology to Heraeus, and Heraeus has licensed certain technology to OrthoCyte. The license grant by OrthoCyte to Heraeus is exclusive and worldwide in the field of bone grafting for all osteoskeleton diseases and injuries, except oral maxillofacial. The license grant by Heraeus to OrthoCyte is exclusive and worldwide in all other fields. Pursuant to the license agreement, each of Heraeus and OrthoCyte will pay certain specified royalties to each other based on their respective net sales of the product developed under the development agreement.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries